Trials / Unknown
UnknownNCT03201185
Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)
Beneficio Del Bloqueo Del Sistema Renina-angiotensina Sobre la evolución clínica y el Remodelado Ventricular Tras la colocación de Una prótesis percutánea aórtica (RASTAVI)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Hospital Clínico Universitario de Valladolid · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators aim to demonstrate that ramipril after transcatheter aortic valve implantation has benefits in terms of prognosis, cardiovascular events and ventricular remodeling (MRI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramipril | Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose). |
Timeline
- Start date
- 2018-02-10
- Primary completion
- 2021-08-13
- Completion
- 2023-08-01
- First posted
- 2017-06-28
- Last updated
- 2021-09-24
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT03201185. Inclusion in this directory is not an endorsement.